Lance Miller Lab
My research is focused on the discovery and characterization of mechanistic and clinically useful aspects of carcinogenesis from a systems biology perspective. Using genomics technologies such as DNA microarrays, my laboratory investigates the transcriptional dynamics and genomic architectures of primary tumors and cell lines at various stages of the oncogenic process and in different clinical contexts. Integrative analysis of genome-wide expression patterns, copy number alterations, and clinicopathologic features allows us to uncover transcriptional programs of mechanistic and prognostic relevance. This strategy has led to the identification and validation of gene expression signatures in liver, breast, ovarian and lung cancers that 1) reflect the activity of specific growth-regulating pathways, 2) define known and novel tumor subtypes, and 3) predict clinical outcomes such as disease recurrence and therapeutic response. Examples include prognostic signatures in breast cancer that reflect the operational configuration of the TP53 pathway (Miller et al, PNAS, 2005) and delineate new prognostic tumor subtypes based on “genetic grade” (Ivshina et al, Cancer Res, 2006). More recently, we have discovered a copy number-related transcriptional signature of disease recurrence in stage I non-small cell lung carcinoma (NSCLC) that outperforms all conventional prognostic factors, and identifies a substantial subgroup of patients that may benefit from adjuvant chemotherapy (Broët, et al, Cancer Res, 2009).
We have also pioneered novel data mining strategies that integrate multiple forms of clinico-genomic information (expression, copy number, patient survival) and are capable of pinpointing known and novel candidate oncogenes. Using this approach, we have recently identified and validated a novel breast cancer oncogene at chromosome 8p11 that promotes transformation, anchorage-independent growth, invasion through matrigel, and tumor formation in mouse xenograft models with an ability to interact with and activate H-Ras. Other candidate genes identified by this method are currently being prioritized for functional characterization based on their potential for therapeutic targeting.
In collaboration with Drs. Frank and Suzy Torti, we have recently discovered a 16-gene Iron Regulatory Gene Signature (IRGS) capable of discriminating breast cancer patient outcomes independent of routine clinical markers. References related to this work and a link to supplemental data files are shown below.
Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010 Aug 4;2(43):43ra56. http://www.ncbi.nlm.nih.gov/pubmed/20686179
Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV, Torti FM. An Iron Regulatory Gene Signature Predicts Outcome in Breast Cancer. Cancer Res. 2011 Aug 29. http://www.ncbi.nlm.nih.gov/pubmed/21875943
Supplemental Data